Pfizer, BioNTech say bivalent booster performs better against BA.5 omicron subvariant

11/04/2022 | by | Uncategorized

Pfizer and BioNTech said that updated data from a Phase 2-3 clinical trial shows the bivalent booster performed better against the BA.4 and BA.5 omicron subvariants.
Source: Test feed

Leave a Comment

Your email address will not be published.

*
*
*